242
Participants
Start Date
February 10, 2017
Primary Completion Date
November 30, 2020
Study Completion Date
November 30, 2020
Botulinum toxin type A
This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
Montefiore Medical Center, The Bronx
Good Shepherd Rehabilitation Network, Allentown
Shriners Hospitals for Children, Philadelphia
Children's National Medical Center, Washington D.C.
Mt. Washington Pediatric Hospital, Baltimore
Shriners Hospitals for Children, Greenville
Clinical Integrative Research Central Atlanta, Atlanta
Nicklaus Children's Hospital, Miami
Laszlo J. Mate, M.D., North Palm Beach
Children's Hospital at Erlanger, Chattanooga
Cleveland Clinic, Cleveland
Akron Children's Hospital, Akron
Dayton Children's Hospital, Dayton
William Beaumont Hospital Pediatric Research, Royal Oak
Children's Hospital of Wisconsin, Milwaukee
Gillette Children's Specialty Healthcare, Saint Paul
Washington University School Of Medicine, St Louis
University of Missouri, Columbia
The Children's Center, Bethany
Texas Children's, Plano
Scottish Rite Hospital for Children, Dallas
Shriners Hospitals for Children, Houston
Texas Children's Hospital, Houston
The Children's Hospital of San Antonio, San Antonio
Utah Neuro Rehabilitation, Murray
Shriners Hospitals for Children, Portland
Valley Health System, Ridgewood
Lead Sponsor
Ipsen
INDUSTRY